AtriCure, Inc. (ATRC)
USD 30.25
(-3.97%)
USD 30.25
(-3.97%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -26.68 Million USD | 27.13% |
| 2022 | -42.66 Million USD | 9.78% |
| 2021 | -47.29 Million USD | -6.92% |
| 2020 | -44.23 Million USD | -33.55% |
| 2019 | -33.12 Million USD | -93.39% |
| 2018 | -17.12 Million USD | 31.43% |
| 2017 | -24.97 Million USD | 19.78% |
| 2016 | -31.13 Million USD | -16.53% |
| 2015 | -26.72 Million USD | -63.33% |
| 2014 | -16.36 Million USD | -50.22% |
| 2013 | -10.89 Million USD | -51.31% |
| 2012 | -7.19 Million USD | -52.16% |
| 2011 | -4.73 Million USD | -48.21% |
| 2010 | -3.19 Million USD | 79.42% |
| 2009 | -15.51 Million USD | -41.04% |
| 2008 | -10.99 Million USD | 12.49% |
| 2007 | -12.56 Million USD | 14.91% |
| 2006 | -14.76 Million USD | -36.72% |
| 2005 | -10.8 Million USD | -91.11% |
| 2004 | -5.65 Million USD | -68.38% |
| 2003 | -3.35 Million USD | 40.71% |
| 2002 | -5.66 Million USD | -80.32% |
| 2001 | -3.14 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -10.91 Million USD | -25.95% |
| 2024 Q2 | -7.16 Million USD | 34.34% |
| 2024 Q3 | -7.4 Million USD | -3.31% |
| 2023 Q1 | -5.78 Million USD | -39.8% |
| 2023 Q4 | -8.66 Million USD | -7.16% |
| 2023 FY | -31.09 Million USD | 27.13% |
| 2023 Q2 | -4.14 Million USD | 28.33% |
| 2023 Q3 | -8.08 Million USD | -95.2% |
| 2022 Q2 | -13.66 Million USD | 3.46% |
| 2022 Q3 | -10.72 Million USD | 21.5% |
| 2022 Q4 | -4.13 Million USD | 61.43% |
| 2022 FY | -42.66 Million USD | 9.78% |
| 2022 Q1 | -14.15 Million USD | -13.18% |
| 2021 Q3 | 98.66 Million USD | 754.43% |
| 2021 Q1 | -15.88 Million USD | 9.24% |
| 2021 Q2 | -15.07 Million USD | 5.09% |
| 2021 FY | -47.29 Million USD | -6.92% |
| 2021 Q4 | -12.5 Million USD | -112.67% |
| 2020 Q4 | -17.5 Million USD | -338.56% |
| 2020 FY | -44.23 Million USD | -33.55% |
| 2020 Q1 | -15.45 Million USD | -0.84% |
| 2020 Q2 | -7.28 Million USD | 52.86% |
| 2020 Q3 | -3.99 Million USD | 45.22% |
| 2019 FY | -33.12 Million USD | -93.39% |
| 2019 Q2 | -3.83 Million USD | 27.84% |
| 2019 Q3 | -8.63 Million USD | -124.98% |
| 2019 Q4 | -15.32 Million USD | -77.45% |
| 2019 Q1 | -5.32 Million USD | -104.07% |
| 2018 Q2 | 958 Thousand USD | 110.16% |
| 2018 FY | -17.12 Million USD | 31.43% |
| 2018 Q4 | -2.6 Million USD | 56.89% |
| 2018 Q3 | -6.04 Million USD | -731.32% |
| 2018 Q1 | -9.43 Million USD | -341.69% |
| 2017 Q2 | -6.35 Million USD | 34.09% |
| 2017 Q1 | -9.64 Million USD | -25.3% |
| 2017 FY | -24.97 Million USD | 19.78% |
| 2017 Q4 | -2.13 Million USD | 68.82% |
| 2017 Q3 | -6.84 Million USD | -7.74% |
| 2016 Q3 | -6.28 Million USD | 18.76% |
| 2016 Q1 | -9.41 Million USD | 11.39% |
| 2016 FY | -31.13 Million USD | -16.53% |
| 2016 Q2 | -7.73 Million USD | 17.85% |
| 2016 Q4 | -7.69 Million USD | -22.41% |
| 2015 Q2 | -4.81 Million USD | 6.32% |
| 2015 FY | -26.72 Million USD | -63.33% |
| 2015 Q3 | -6.12 Million USD | -27.14% |
| 2015 Q4 | -10.63 Million USD | -73.49% |
| 2015 Q1 | -5.14 Million USD | -7.64% |
| 2014 Q1 | -7.92 Million USD | -63.81% |
| 2014 FY | -16.36 Million USD | -50.22% |
| 2014 Q2 | -2.85 Million USD | 64.0% |
| 2014 Q4 | -4.77 Million USD | -495.14% |
| 2014 Q3 | -803 Thousand USD | 71.85% |
| 2013 Q2 | -1.63 Million USD | 8.94% |
| 2013 Q1 | -1.8 Million USD | 2.81% |
| 2013 Q4 | -4.83 Million USD | -85.08% |
| 2013 Q3 | -2.61 Million USD | -59.49% |
| 2013 FY | -10.89 Million USD | -51.31% |
| 2012 Q3 | -2.52 Million USD | -91.59% |
| 2012 Q4 | -1.85 Million USD | 26.77% |
| 2012 Q2 | -1.32 Million USD | 11.76% |
| 2012 FY | -7.19 Million USD | -52.16% |
| 2012 Q1 | -1.49 Million USD | 11.72% |
| 2011 Q1 | -1.07 Million USD | -351.79% |
| 2011 Q4 | -1.69 Million USD | -42.34% |
| 2011 FY | -4.73 Million USD | -48.21% |
| 2011 Q3 | -1.19 Million USD | -54.38% |
| 2011 Q2 | -771.16 Thousand USD | 28.21% |
| 2010 Q4 | -237.76 Thousand USD | 71.38% |
| 2010 Q2 | -432.86 Thousand USD | 74.39% |
| 2010 Q3 | -830.88 Thousand USD | -91.95% |
| 2010 Q1 | -1.69 Million USD | 20.05% |
| 2010 FY | -3.19 Million USD | 79.42% |
| 2009 Q1 | -7.93 Million USD | -129.36% |
| 2009 Q4 | -2.11 Million USD | 52.3% |
| 2009 Q3 | -4.43 Million USD | -328.86% |
| 2009 Q2 | -1.03 Million USD | 86.97% |
| 2009 FY | -15.51 Million USD | -41.04% |
| 2008 Q3 | -1.81 Million USD | 0.4% |
| 2008 FY | -10.99 Million USD | 12.49% |
| 2008 Q1 | -3.89 Million USD | -139.48% |
| 2008 Q2 | -1.82 Million USD | 53.15% |
| 2008 Q4 | -3.45 Million USD | -90.22% |
| 2007 Q1 | -4.87 Million USD | -9.38% |
| 2007 FY | -12.56 Million USD | 14.91% |
| 2007 Q2 | -3.15 Million USD | 35.15% |
| 2007 Q4 | -1.62 Million USD | 44.07% |
| 2007 Q3 | -2.9 Million USD | 7.94% |
| 2006 FY | -14.76 Million USD | -36.72% |
| 2006 Q1 | -3.36 Million USD | 21.57% |
| 2006 Q2 | -3.55 Million USD | -5.46% |
| 2006 Q3 | -3.39 Million USD | 4.56% |
| 2006 Q4 | -4.45 Million USD | -31.35% |
| 2005 Q3 | -3.76 Million USD | -176.72% |
| 2005 Q4 | -4.29 Million USD | -14.05% |
| 2005 Q1 | -1.41 Million USD | 44.73% |
| 2005 FY | -10.8 Million USD | -91.11% |
| 2005 Q2 | -1.36 Million USD | 3.5% |
| 2004 FY | -5.65 Million USD | -68.38% |
| 2004 Q4 | -2.55 Million USD | -49.28% |
| 2004 Q2 | -223.9 Thousand USD | 0.0% |
| 2004 Q3 | -1.7 Million USD | -663.65% |
| 2003 FY | -3.35 Million USD | 40.71% |
| 2002 FY | -5.66 Million USD | -80.32% |
| 2001 FY | -3.14 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -57.66 Million USD | 53.73% |
| AngioDynamics, Inc. | -97.71 Million USD | 72.694% |
| Avinger, Inc. | -16.63 Million USD | -60.403% |
| Azenta, Inc. | -73.12 Million USD | 63.511% |
| BioLife Solutions, Inc. | -70.82 Million USD | 62.325% |
| The Cooper Companies, Inc. | 533.1 Million USD | 105.005% |
| Daxor Corporation | -177.07 Thousand USD | -14968.756% |
| Ekso Bionics Holdings, Inc. | -15.11 Million USD | -76.568% |
| Femasys Inc. | -14.5 Million USD | -83.914% |
| GlucoTrack, Inc. | -7.1 Million USD | -275.605% |
| Harvard Bioscience, Inc. | 1.89 Million USD | 1508.817% |
| Hologic, Inc. | 882.6 Million USD | 103.023% |
| ICU Medical, Inc. | 22.82 Million USD | 216.903% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 101.51% |
| KORU Medical Systems, Inc. | -10.26 Million USD | -159.816% |
| LeMaitre Vascular, Inc. | 37.08 Million USD | 171.957% |
| Innovative Eyewear, Inc. | -6.9 Million USD | -286.68% |
| Innovative Eyewear, Inc. | -6.9 Million USD | -286.68% |
| Masimo Corporation | 136.5 Million USD | 119.548% |
| Microbot Medical Inc. | -9.85 Million USD | -170.756% |
| Meihua International Medical Technologies Co., Ltd. | 14.67 Million USD | 281.827% |
| Merit Medical Systems, Inc. | 123.94 Million USD | 121.528% |
| Nephros, Inc. | -1.59 Million USD | -1575.016% |
| NovoCure Limited | -232.87 Million USD | 88.542% |
| NEXGEL, Inc. | -3.47 Million USD | -667.414% |
| NEXGEL, Inc. | -3.47 Million USD | -667.414% |
| Singular Genomics Systems, Inc. | -102.8 Million USD | 74.044% |
| OraSure Technologies, Inc. | 54.07 Million USD | 149.341% |
| Pro-Dex, Inc. | 7.17 Million USD | 471.992% |
| Pulse Biosciences, Inc. | -43.57 Million USD | 38.764% |
| Predictive Oncology Inc. | -13.92 Million USD | -91.67% |
| Precision Optics Corporation, Inc. | -2.72 Million USD | -879.432% |
| QuidelOrtho Corporation | 139.1 Million USD | 119.183% |
| Repligen Corporation | 54.57 Million USD | 148.891% |
| Sanara MedTech Inc. | -4.21 Million USD | -533.026% |
| STAAR Surgical Company | 28.09 Million USD | 194.967% |
| Sharps Technology, Inc. | -10.12 Million USD | -163.493% |
| Utah Medical Products, Inc. | 16.77 Million USD | 259.045% |
| DENTSPLY SIRONA Inc. | -85 Million USD | 68.608% |
| Jin Medical International Ltd. | 2.86 Million USD | 1030.609% |